Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing
August 21 2023 - 7:00AM
Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a medical technology company driving a
fundamental shift in the surgical treatment of hallux valgus
(commonly known as bunions) through its Lapiplasty® 3D Bunion
Correction™ Procedure, today announced Nathan Minnich has been
appointed Sr. Vice President, Marketing, effective immediately. In
this new position, Mr. Minnich will lead all aspects of Treace’s
marketing efforts, with a focus on expanding the Company’s
physician outreach, patient awareness and market penetration
efforts.
“I am delighted to welcome Nathan to the Treace
team,” said John T. Treace, CEO, Founder and Board Member of
Treace. “During his career, Nathan has led the development,
implementation and execution of successful marketing and
direct-to-consumer strategies and programs for several medical
technology and healthcare businesses, including most recently at
Align Technology. His proven track record of success in building
class-leading marketing programs will be instrumental as we
continue to focus on driving revenue growth, advancing our patient
awareness/DTC initiatives, and launching new products, including
our SpeedPlate™ Implant Fixation Platform and Micro-Lapiplasty™
System. This is an exciting time for Treace, and I’m confident that
Nathan’s appointment will further bolster our ability to capitalize
on the growth opportunities in front of us and accelerate our
market performance.”
“I am thrilled to be joining Treace, and I look
forward to furthering its goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities,” said Nathan Minnich. “Treace’s patented
Lapiplasty® 3D Bunion Correction™ Procedure and its
Adductoplasty® Midfoot Correction System both provide
disruptive technology solutions in one of the largest and most
underserved markets in orthopaedics."
Mr. Minnich is an accomplished marketing leader
with significant senior management experience in the healthcare and
medical device sectors. He most recently served as Vice President,
Americas at Align Technology, Inc. where he led a consumer
marketing and business innovation team for the Invisalign® System.
Prior to Align, he was Vice President of Neuromodulation at
LivaNova PLC from 2014 to 2019. Earlier in his career, Mr. Minnich
held several sales and marketing roles of increasing responsibility
at UCB, AstraZeneca and Johnson & Johnson. Mr. Minnich received
a B.S. in Health Policy & Administration from Penn State
University and an M.B.A. from Centenary
University.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements other than statements of historical fact are
forward-looking statements, including, but not limited to the
Company’s ability to capitalize on the growth opportunities in
front of it, accelerate its market performance and to set the
standard in the treatment of hallux valgus. Forward-looking
statements are based on management’s current assumptions and
expectations of future events and trends, which affect or may
affect the Company’s business, strategy, operations or financial
performance, and actual results and other events may differ
materially from those expressed or implied in such statements due
to numerous risks and uncertainties. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. Factors that could cause actual results
or other events to differ materially from those contemplated in
this press release can be found in the Risk Factors section of
Treace’s public filings with the Securities and Exchange Commission
(SEC), including its Annual Report on Form 10-K for the year ended
December 31, 2022, filed with the SEC on March 8, 2023 and its
Quarterly Report on Form 10-Q for the quarter ended March 31, 2023,
filed with the SEC on May 9, 2023. Because forward-looking
statements are inherently subject to risks and uncertainties, you
should not rely on these forward-looking statements as predictions
of future events. These forward-looking statements speak only as of
their date and, except to the extent required by law, the Company
undertakes no obligation to update these statements, whether as a
result of any new information, future developments or
otherwise.
Internet Posting of
InformationTreace routinely posts information that may be
important to investors in the “Investor Relations” section of its
website at www.treace.com. The Company encourages investors and
potential investors to consult the Treace website regularly for
important information about Treace.
About Treace Medical
ConceptsTreace Medical Concepts, Inc. is a medical
technology company with the goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities. Bunions are complex 3-dimensional deformities that
originate from an unstable joint in the middle of the foot and
affect approximately 65 million Americans, of which Treace
estimates 1.1 million are annual surgical candidates. Treace has
pioneered and patented the Lapiplasty® 3D Bunion Correction™ System
– a combination of instruments, implants, and surgical methods
designed to surgically correct all 3 planes of the bunion deformity
and secure the unstable joint, addressing the root cause of the
bunion and helping patients get back to their active lifestyles.
Treace expanded its offering with the Adductoplasty® Midfoot
Correction System, designed for reproducible surgical correction of
the midfoot to provide further support to hallux valgus patients.
For more information, please visit www.treace.com.
To learn more about Treace, connect with us on
LinkedIn, Twitter, Facebook and Instagram.
Contacts:
Treace Medical ConceptsJulie
Dewey, IRCChief Communications & IR
Officerjddewey@treace.com(209) 613-6945
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From Apr 2024 to May 2024
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From May 2023 to May 2024